
Health Check: LTR Pharma finds fast-track path to US erectile dysfunction market
It’s up and go time for LTR in the US market All the budget healthcare news – and it’s a short item Prescient launches phase 2a study for a rare blood cancer The developer of a nasal spray-mist erectile dysfunction (ED) treatment, LTR Pharma (ASX:LTP) …